Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.

You may also be interested in...



Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008

European Commission approves marketing for Epo-zeta products Hospira's Retacrit, Stada Arzneimittel's Silapo on basis of similarity to J&J's Procrit.

Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008

European Commission approves marketing for Epo-zeta products Hospira's Retacrit, Stada Arzneimittel's Silapo on basis of similarity to J&J's Procrit.

Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy

Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel